Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Young E Whang

Showing results (1-10 of 62) with videos related to

Pageof 7
Sort By:
American Journal of Clinical Oncology|August 2, 2002
Hypertriglyceridemia and pancreatitis associated with estramustine phosphateEric L Olson, Young E Whang
Investigational New Drugs|December 4, 2014
Posterior reversible encephalopathy syndrome induced by enzalutamide in a patient with castration-resistant prostate cancerDaniel J Crona, Young E Whang
Oncogene|January 23, 2002
PTEN sensitizes prostate cancer cells to death receptor-mediated and drug-induced apoptosis through a FADD-dependent pathwayXiu-Juan Yuan, Young E Whang
JAMA Oncology|July 17, 2015
Genomic Profiling of Cancers of Unknown Primary Site: The Next StepsYoung E Whang, D Neil Hayes
Cancers|June 13, 2017
Androgen Receptor-Dependent and -Independent Mechanisms Involved in Prostate Cancer Therapy ResistanceDaniel J Crona, Young E Whang
Current Opinion in Oncology|June 5, 2003
Renal cell carcinomaYoung E Whang, Paul A Godley
Annals of Translational Medicine|November 22, 2016
Application of liquid biopsies to identify genomic factors associated with therapy resistance in castration resistant prostate cancerDaniel J Crona, Young E Whang
Expert Review of Anticancer Therapy|June 15, 2014
Mechanisms of acquired resistance to androgen receptor targeting drugs in castration-resistant prostate cancerDavid D Chism, Dinuka De Silva, Young E Whang
Anti-Cancer Drugs|March 2, 2011
Response to degarelix after resistance to luteinizing hormone-releasing hormone agonist therapy for metastatic prostate cancerRyan S Raddin, Christine M Walko, Young E Whang
Investigational New Drugs|June 30, 2018
Cabozantinib-induced serum creatine kinase elevation and musculoskeletal complaintsSarah E Stump, Young E Whang, Daniel J Crona
Pageof 7

Showing results (1-10 of 62) with videos related to

Sort By:
Pageof 7
American Journal of Clinical Oncology|August 2, 2002
Hypertriglyceridemia and pancreatitis associated with estramustine phosphateEric L Olson, Young E Whang
Investigational New Drugs|December 4, 2014
Posterior reversible encephalopathy syndrome induced by enzalutamide in a patient with castration-resistant prostate cancerDaniel J Crona, Young E Whang
Oncogene|January 23, 2002
PTEN sensitizes prostate cancer cells to death receptor-mediated and drug-induced apoptosis through a FADD-dependent pathwayXiu-Juan Yuan, Young E Whang
JAMA Oncology|July 17, 2015
Genomic Profiling of Cancers of Unknown Primary Site: The Next StepsYoung E Whang, D Neil Hayes
Cancers|June 13, 2017
Androgen Receptor-Dependent and -Independent Mechanisms Involved in Prostate Cancer Therapy ResistanceDaniel J Crona, Young E Whang
Current Opinion in Oncology|June 5, 2003
Renal cell carcinomaYoung E Whang, Paul A Godley
Annals of Translational Medicine|November 22, 2016
Application of liquid biopsies to identify genomic factors associated with therapy resistance in castration resistant prostate cancerDaniel J Crona, Young E Whang
Expert Review of Anticancer Therapy|June 15, 2014
Mechanisms of acquired resistance to androgen receptor targeting drugs in castration-resistant prostate cancerDavid D Chism, Dinuka De Silva, Young E Whang
Anti-Cancer Drugs|March 2, 2011
Response to degarelix after resistance to luteinizing hormone-releasing hormone agonist therapy for metastatic prostate cancerRyan S Raddin, Christine M Walko, Young E Whang
Investigational New Drugs|June 30, 2018
Cabozantinib-induced serum creatine kinase elevation and musculoskeletal complaintsSarah E Stump, Young E Whang, Daniel J Crona
Pageof 7